8h agoThe FlyBULLISH 63Product/PR
Archived explainer. For the current picture see today's ORKA page.
Why Is ORUKA THERAPEUTICS I (ORKA) Stock Down Today?
By the Top Tier Newswire AI Desk · September 23, 2026 at 11:42 AM ET · reviewed against 5 wire stories
ORUKA THERAPEUTICS I (ORKA) is down -8.43% in the latest session. Our newswire has captured 5 stories on ORKA across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Oruka Therapeutics I stock fell 8.43% to $86.58 in morning trading on September 23, 2026, despite positive Week 28 data from its Phase 2a EVERLAST-A trial of ORKA-001 in plaque psoriasis. The stock opened higher but quickly reversed course, hitting a session low of $86.46. The decline came amid mixed market reactions to the clinical data and recent insider selling.
What Happened
The company reported that PASI 100 increased to 71.4% and PASI 90 to 87.3% in the active arm of the trial, despite no dosing after Week 4. These results indicate deepening efficacy of ORKA-001 without additional treatment. However, the stock declined as investors weighed the implications of the data and recent insider transactions. Three insiders, including the Chief Medical Officer, sold shares in the last week. Analysts from HC Wainwright & Co., Guggenheim, and BTIG have maintained Buy ratings with price targets ranging from $120 to $200, but the market appears to have discounted these views in the short term.
What The Data Shows
The stock opened at $95.70, a 1.2% gap up from the prior close, but fell steadily throughout the session. Volume was 0.5 million shares, or 0.4 times the 3-month daily average. Over the previous eight sessions, the stock had risen 5.2% from $91.00 to $95.72. The company’s market cap is $6.3 billion, with a trailing twelve-month EPS of -2.02. The stock has traded between $14.89 and $115.52 over the past 52 weeks. On September 23, it printed 32 fresh 52-week lows and two 52-week highs.
What To Watch
The stock is currently without an imminent earnings report. Investors will likely monitor coverage breadth and analyst reactions in the coming days, as well as any new developments in the ORKA-001 trial or corporate actions.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ORKA by the numbers
Last: $86.58Session: -8.43%7 sessions: -3.46%Coverage: 5 stories / 5 sourcesAI sentiment: 58/100 (bullish)Mkt cap: $6.3B52w: $14.89 to $115.52
The headlines behind the move
9h agoInvestorsHubBEARISH 38Product/PR
Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data
Oruka Therapeutics shares fall 5% after the company reports Week 28 data from its Phase 2a EVERLAST-A trial of ORKA-001 in plaque psoriasis.
10h agoInvesting.com MarketsBEARISH 42Product/PR
Oruka Therapeutics stock falls despite positive trial data
Oruka Therapeutics stock falls despite positive trial data
10h agoMarketChameleonBULLISH 73Product/PR
Oruka’s ORKA-001 posts rising Week 28 skin-clearance rates with no dosing after Week 4 September 23, 2026
Oruka Therapeutics reported positive Week 28 data from its EVERLAST-A Phase 2a trial of ORKA-001 in plaque psoriasis, with PASI 100 rising to 71.4% and PASI 90 to 87.3% despite no dosing after Week 4 in the active arm. The company said safety remained consistent with the IL-23p19 class, and it expects 52-week EVERLAST-A data in December 2026 and 16-week EVERLAST-B data in 4Q 2026.
11h agoBusiness InsiderBULLISH 73Product/PR
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ORKA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ORKA move explainers: 2026-09-23